K.J Somaiya Hospital and Research Centre

Somaiya Vidyavihar University

Hemophilia B

Hemophilia A

Sickle Cell Anemia

Hydroxyurea

decitabine

tetrahydrouridine

Catalyst Biosciences

Novo Nordisk

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease. NDec is a combination of two medicines (decitabine-tetrahydrouridine). Both medicines are new for the treatment of sickle cell disease. Participants who are not taking Hydroxyurea (HU) will get NDec, NDec and placebo, or placebo. Participants who are on HU treatment before joining the study will get NDec, NDec and placebo, or continue on HU. Which treatment participants get is decided by chance. Participants getting NDec and/or Placebo will get capsules to take twice weekly. The study will last for about a year.

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

Somaiya Vidyavihar University | K.J Somaiya Hospital and Research Centre

Site insights

Work at this site?

Active trials

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease (ASCENT1)

Trial sponsors